Could a common drug help cancer patients keep their appetite?

NCT ID NCT06995508

Recruiting now Symptom relief Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding olanzapine to standard care helps manage appetite loss in head and neck cancer patients undergoing chemoradiation. About 66 adults will receive either olanzapine plus standard symptom management or standard care alone. The main goal is to see if olanzapine helps patients maintain weight during treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olanzapine
What this could lead to: If it works, this could offer a way to reduce weight loss and improve appetite during cancer treatment.
What could go wrong: This is a small, early-phase trial, so results may not apply broadly. Olanzapine can cause side effects like drowsiness or metabolic changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER-ASSOCIATED ANOREXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma metastatic squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER-ASSOCIATED ANOREXIA HEAD AND NECK SQUAMOUS CELL CARCINOMA NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY

Contacts and locations

Show contact details

Locations

Roswell Park Cancer Institute
RECRUITING

Buffalo, New York, 14263, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.